Observ/antiTNF/IBD/Surgery

Multicentre prospective observational study of patients with IBD undergoing intra-abdominal surgery.

Current antiTNF defined as use within 12 weeks of surgery, and serum was collected for drug-level analysis.

<u>Primary endpoint:</u> ocurrence of any infection within 30 days from surgery.

Results:


- Any infection 18.1% antiTNF vs not exposed 20.2%, p=0.469
- Surgical site infection, 12% antiTNF vs not 12.6%, p=0.889
- No association on multivariable analysis between exposure to antiTNF and any infection or surgical site infection.
- Detectable levels of antiTNF not associated to any infection or surgical site infection

Conclusion:

Preoperative antiTNF exposure was not associated with postoperative infectious complications in a large prospective multicenter cohort.

Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease UndergoingIntra-abdominal Surgery

Frequency of Any Infection by Patient Reported TNFi Exposure



Frequency of Surgical Site Infection Type by Patient Reported TNFi Exposure

